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Abstract
Background: Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops
brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore,
outcomes following ipilimumab and radiation are of interest, especially given case reports and animal studies
suggest combined treatment may generate abscopal responses outside the radiation field.
Findings: We reviewed sixteen consecutive melanoma patients who received 1 to 8 courses of radiation, with a
sum total of 51, systematically evaluating abscopal responses by following the largest extra-cranial lesion. We also
reviewed other series of patients treated with cranial radiation and ipilimumab.
Our patients received between 1 and 8 courses of cranial radiation. Four patients received radiation concurrently
with ipilimumab. Median survival was 14 months, and 17 months in patients initially treated with SRS. Interestingly,
after radiotherapy, there was a 2.8-fold increased likelihood that the rate of extra-cranial index lesion response
improved that didn’t reach statistical significance (p = 0.07); this was more pronounced when ipilimumab was
administered within three months of radiation (p < 0.01).
Conclusion: Our experience and review of recently published series suggest ipilimumab and cranial radiation is
well tolerated and can result in prolonged survival. Timing of ipilimumab administration in relation to radiation may
impact outcomes. Additionally, our results demonstrate a trend for favorable systemic response following radiotherapy
worthy of further evaluation in studies powered to detect potential synergies between radiation and immunotherapy.
Keywords: Melanoma, Ipilimumab, Immunotherapy, Radiation, Abscopal effect, Brain metastases, Stereotactic
radiosurgery
Findings
Introduction
Approximately 30–50 % of metastatic melanoma pa-
tients develop brain metastases, which have historically
been associated with limited survival of approximately
four months [1]. Treatment typically includes whole-
brain radiation (WBRT) or stereotactic radiosurgery
(SRS) [2]. Ipilimumab has also demonstrated promise
treating brain metastases in both a prospective trial [3]
and a randomized trial including patients with intracra-
nial disease [4].
Given the survival benefit associated with ipilimumab
[4, 5] the combination of ipilimumab and cranial radio-
therapy is of interest. Additionally, the effect of radiation
and ipilimumab is intriguing given case reports and
preclinical studies that suggest abscopal responses after
radiation and immunotherapy [6, 7]. We sought to sys-
tematically explore this phenomenon by reviewing our
experience and other recently published series describing
patients treated with the combination of ipilimumab and
cranial radiation.
Materials and methods
Patients and treatment
Sixteen consecutive patients with malignant melanoma
were treated with ipilimumab and at least one instance
of cranial radiation between 2008 and 2013 at our insti-
tution. This study was approved by our institutional
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review board as described in the Ackowledgments. No
patient consent was required as this was a retrospective
study.
Ipilimumab was generally given every three weeks for
a total of four doses at a dose of either 3 mg/kg (n = 14)
or 10 mg/kg (n = 2); patients achieving clinical benefit
were offered maintenance therapy every twelve weeks.
Cranial radiation was either WBRT or SRS. No patients
received SRS as a planned boost. SRS was delivered
using the Cyberknife (Accuray, Sunnvale, CA) system
prescribed to the clinical tumor volume (CTV) which
was equivalent to the planning tumor volume.
Evaluation of response
A multimodality team including a medical, and radiation
oncologist along with a neurosurgeon regularly followed
all patients at least every 3 months until death. While re-
ceiving ipilimumab, evaluation of systemic response
using mWHO criteria was performed with computed
tomography or magnetic resonance imaging generally
after four initial cycles and then at three-month intervals
unless otherwise indicated. To evaluate abscopal effect,
we extracted the longest diameter of the largest extra-
cranial “index” lesion from the medical record, and
changes between subsequent scans were calculated. A
“delta-delta” was calculated as the difference in percent
change of the index lesion on the two consecutive scans
performed prior to radiation therapy as compared with
the difference in the consecutive scans performed pre-
and post-radiation as described previously [8].
Statistical analysis
We calculated overall survival from the last day of the
first cranial radiation course using the Kaplan-Meier
method. Responses before and after radiotherapy were
compared using McNemar’s and binomial tests for clus-
tered data. Two-group exact tests for clustered data were
used to explore the impact of treatment timing on re-
sponse. All statistical tests were two-sided.
Results
Patient characteristics
Sixteen patients treated with radiation and ipilimumab
received between one and eight courses of cranial radi-
ation for a total of 51 courses (Table 1). Most patients
(n = 10, 63 %) received four doses of ipilimumab; three
patients received more than four doses as maintenance
therapy, and three patients received less than 4 cycles
because of disease progression. Median age at the time of
first radiotherapy treatment was 57 (range 40 – 85 years).
Of the 51 courses of brain-directed radiotherapy, 46
(90 %) were delivered by SRS. The remaining 5 radiation
treatments were given as WBRT. WBRT was administered
as the first radiation course in two patients who ultimately
received subsequent SRS treatments, after previous SRS
treatments in two patients, and in one patient who did
not receive subsequent brain-directed radiotherapy. The
median dose administered was 22 Gray (Gy, range 18 –
24 Gy) for all SRS treatments and 36 Gy (range 20–36 Gy)
for all WBRT courses.
Seven patients received ipilimumab before brain-
directed radiation, and 5 patients began ipilimumab after
radiation. Four patients received radiation at some point
while undergoing ipilimumab treatment and continued
ipilimumab following radiation (concurrent treatment).
Among these four patients who received concurrent
treatment, in one patient, both treatments were given on
the same day, and in two patients, concurrent treatment
Table 1 Patient (n = 16) and radiation treatment (n = 51)
characteristics
Patients
Male sex 13 (81 %)
Age at time of initial brain radiation,
median (range)
57 years
(40 – 85 years)
Ipilimumab dosing
10 mg/kg 2 (13 %)
3 mg/kg 14 (88 %)
Number of ipilimumab treatments, median (range) 4 (1 – 17)
Radiation Treatment
Number of radiation courses per patient,
median (range)
3 (1–8)
Number of lesions irradiated
1 23 (45 %)
2-3 15 (29 %)
>3 13 (25 %)
Type of radiotherapya
Whole brain radiation 5 (10 %)
Stereotactic Radiosurgery 46 (90 %)
Radiation Dose (Gray), median (range)
Whole brain radiation 36 Gy
(20 – 36 Gy)
Stereotactic Radiosurgeryb 22 Gy
(18 – 24 Gy)
Location of index lesion
Skin/subcutaneous tissue/lymph nodes 8 (26 %)
Lung 14 (45 %)
Other 9 (29 %)
None 3
Not imaged / Unknown 17
Abbreviations: Gy Gray
aWhole brain treatment given in 2 Gy fractions. Stereotactic radiosurgery
treatments were administered in 1–5 fractions
bIf multiple lesions were irradiated to different doses, the mean dose was used
for tabulation
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occurred multiple times. Overall, ipilimumab treatment
was given within 3 months of radiation in 21 instances
(41 %); in the remaining 59 %, ipilimumab was adminis-
tered a median of 3.5 months prior to radiation.
Outcomes
Median overall survival (OS) following first radiation
treatment to the brain among all patients was 14.4 months,
with a maximum OS of 50 months (Fig. 1). OS was
17 months in patients initially treated with SRS, and
19 months in patients that required multiple courses of
cranial radiation. Patients who received SRS prior to initi-
ating ipilimumab had superior OS as compared with pa-
tients who started ipilimumab prior to receiving SRS
(median 26 months compared with 6 months, p < 0.001)
despite similar age at diagnosis, number of lesions irradi-
ated, number of cycles and dose of ipilimumab, and loca-
tion of index lesion. Patients who received radiation
concurrent with ipilimumab did not develop any signifi-
cant immune related adverse events and had a median OS
of 18 months.
Sequential imaging of systemic index lesions was per-
formed before and after radiation in 31 instances. These
lesions were most commonly located in the chest (45 %,
Table 1). On the subsequent scan after radiation, in 11
of these 31 instances (35 %) the index lesion decreased
in size as compared with the scan preceding radiation
therapy. In comparison, in 25 of these 31 instances the
index lesion size was also comparable on two scans prior
to radiation treatment, and only 4 (17 %) demonstrated
a favorable response (p = 0.20, McNemar’s test for clus-
tered paired data). Among the 31 instances where im-
aging was available before and after radiation, there were
22 instances where two consecutive scans were also
performed prior to the receipt of radiotherapy. In these
cases, the response rate of index lesion response im-
proved in 50 % of instances following radiation in com-
parison to worsening in 18 % (p = 0.07, binomial test for
clustered data). In contrast, there was no significant as-
sociation between time elapsed since first ipilimumab
administration and favorable kinetics (p = 0.88).
We examined the significance of the timing of ipilimu-
mab in relation to radiation (Fig. 2). In the 31 instances
where imaging was performed sequentially before and
after radiation, index lesions were significantly more
likely to decrease in size if ipilimumab was administered
within the three months surrounding radiation treat-
ment (63 % compared with 7 %, p = 0.003 by two-group
exact test for clustered data).
Discussion
We describe our experience treating melanoma patients
with cranial radiation and ipilimumab. We report a me-
dian OS greater than 1 year in 16 patients that received
a total of 51 radiotherapy courses including patients who
received WBRT, multiple courses for recurrent disease,
and patients who received radiotherapy concurrent with
ipilimumab. These results compare favorably with his-
torical series of melanoma patients with brain metasta-
ses treated with surgery and radiotherapy that describe
median OS of less than 9 months, and less than 4 months
in patients treated with radiotherapy alone [1]. Two-year
OS in our series was 25 % and prolonged OS of over
50 months was observed. Similar favorable outcomes have
also been seen in patients treated concurrently with ipili-
mumab and radiation of extra cranial lesions [9].
Review of the literature revealed 5 other recently pub-
lished studies or abstracts that describe outcomes in 117
additional patients treated with the combination of cra-
nial radiation and ipilimumab (Table 2). Ours is the only
study to include patients initially treated with WBRT.
None reported unacceptable rates immune related tox-
icity; however there are several reports of radionecrosis
perhaps mediated in part by the immune system. Median
OS in these studies ranged from approximately 5 months
to almost 2.5 years, with favorable 1 and 2 year OS rates
ranging from 40 − 67 %. The majority of these studies
noted improved OS when SRS was administered prior to
ipilimumab, as was observed in our study. In our study,
baseline characteristics were similar between patients that
received SRS prior or after ipilimumab; however, the lim-
ited numbers unfortunately precludes complex multivari-
ate analysis. Although we were unable to adjust for
unmeasured confounding variables, we currently find a
strong association that would likely remain significant
even if attenuated by other factors.
Interestingly, the two other studies that reported the
shortest median OS reported routine use of prophylactic
Fig. 1 Patient Survival. Survival from first radiation treatment
course (n = 16)
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steroids at the time of SRS [10, 11]. Although data sug-
gests that steroids administered for ipilimumab-induced
immune-related adverse events do not adversely impact
the efficacy of treatment, further evaluation of prophy-
lactic steroids for asymptomatic patients may be war-
ranted [12, 13].
Our analysis included evaluation of index systemic le-
sion response in relation to the timing of brain-directed
radiotherapy and ipilimumab administration. Other
retrospective studies have suggested radiation may be as-
sociated with a favorable systemic response in patients
progressing on ipilimumab who receive radiation to a
variety of sites [8, 14]. Similarly, we found that index le-
sions decreased in size after brain directed radiotherapy
in 63 % patients who received both radiotherapy and
ipilimumab within a three-month span. The limited num-
ber of patients analyzed constrained our power to detect
statistically significant differences; however index lesions
were approximately twice as likely to decrease in size on
imaging following radiation, with the additive benefit of
improved kinetics of response. Although delayed index
lesion response to ipilimumab or favorable response to
ipilimumab as compared to other systemic agents may
partially explain these results, ipilimumab had been ad-
ministered for more than three months prior to radiother-
apy in 27 (53 %) of instances and there was no significant
association between duration of ipilimumab and favorable
kinetics.
Radiation has potential immunogenic properties [15, 16]
and the combination of ipilimumab and local radiotherapy
Fig. 2 Change in index lesion response. Waterfall plots demonstrating index lesion responses for instances where sequential radiologic measurements
were available. Both the percent change in the longest diameter of the index lesion after cranial irradiation (top, n= 29) and “delta-delta”, difference in
percent change from the two imaging studies performed before cranial irradiation and before and after radiation (bottom, n= 22) are shown. Instances
where ipilimumab was not given within three months of radiation are shown in blue, administration of both ipilimumab and radiation
within a three-month span are shown in red
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Table 2 Review of studies evaluating patients treated with cranial radiation and ipilimumab
N Median overall survival
(mos)
Landmark survival Steroid use Timing issues Radiation necrosis requiring
surgery
Kiess et al. [10] 46 12.4 1 yr OS 40–65 % depending on timing
of ipi
Routine use of ppx steroids SRS before or during ipi associated
with improved OS
5 patients
Knisely et al.
[19]
27 21.3 2 yr OS 47 % Not reported SRS before ipi associated with trend
towards improved survival
3 patients
Mathew et al.
[11]
25 5a 6 mos OS 56 % Routine use of ppx steroids Not reported 0
Schoenfeld et al.
(current study)
16 14.4 1 yr OS 54 % No routine use of ppx
steroids
SRS before ipi associated with better
survival
0
Shoukat et al.
[20]
11 28.3 1 yr OS 67 % Not reported Not reported 3 patientsb
Tazi et al. [21] 10 29.3 2 yr OS 58 % Not reported All patients received SRS before or
during ipi
Not reported
Abbreviations: mos months, ppx prophylactic, OS overall survival, ipi ipilimumab, SRS stereotactic radiosurgery
aEstimated from survival curve
bUse of surgery not specified
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increased systemic anti-tumor responses and improved
OS in a mouse model of breast carcinoma [17]. Case re-
ports and small studies have suggested similar radiation-
stimulated immune phenomenon in humans, with the
combination of radiation and ipilimumab resulting in in-
creased antigen targeting, decreased numbers of inhibitory
myeloid-derived suppressor cells, and increased levels of
anti-tumor antibodies and circulating activated T-cells
[6, 7, 18]. Our results add to this growing body of evi-
dence that suggest that future studies should continue
to examine the potential synergies between radiother-
apy and immunotherapy.
Abbreviations
WBRT: Whole brain radiation therapy; SRS: Stereotactic radiosurgery;
Ipi: Ipilimumab; OS: Overall survival.
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